Novel osteoprotective nanocochleate formulation: A dual combination therapy-codelivery system against glucocorticoid induced osteoporosis

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

“…AL was purchased from Dr. Abidi Pharmaceutical Company (Tehran, Iran), methylprednisolone (MP) from Pfizer Pharmaceuticals (USA), and curcumin from Sigma (USA). PSL and PSL‐Cur were prepared by the modified liposome formulation procedure as described by Eskandarynasab, Etemad‐Moghadam, et al (2020). The liposome formation of PSL‐Cu in vesicular shape and its approximate size range were determined using photomicroscopy and Zetasizer, respectively, which are shown in Figure 1.…”

“…The subeffective doses of PSL and Cur were selected at 20 and 25 mg/kg, respectively, and the treatments continued for 3 weeks. AL (10 μg/kg) was prepared by dissolving into saline, which was used in the experimental models as the standard drug of osteoporosis (Cho et al, 2013; Eskandarynasab, Etemad‐Moghadam, et al, 2020). The animals were divided into six groups with seven rats per group as follows: Control group (0.2 ml saline po daily); MP group (10 mg/kg/day); MP+AL group (MP 10 mg/kg/day + AL10 μg/kg/day); MP+Cur group (MP 10 mg/kg/day + Cur 25 mg/kg/day); MP+PSL group (MP 10 mg/kg/day + PSL 20 mg/kg/day); MP+PSL‐Cur group (MP 10 mg/kg/day + PSL‐Cur as Cur 25 mg/kg/day and PSL 20 mg/kg/day). …”

“…On the other hand, long‐term bisphosphonate therapy can lead to severe adverse effects such as atypical femoral fractures (AFFS), osteonecrosis of the jaw (ONJ), AND esophageal cancer (Reyes et al, 2016). Turning to natural products such as curcumin (Cur) or phosphatidylserine combined with the existing anti‐osteoporotic drugs is recommended in order to reduce the adverse effects of drug usage in the long term (An et al, 2016; Eskandarynasab, Doustimotlagh, et al, 2020; Eskandarynasab, Etemad‐Moghadam, et al, 2020; Kim et al, 2011).…”

Novel Nanohydroxyapatite (nHAp)-Based Scaffold Doped with Iron Oxide Nanoparticles (IO), Functionalized with Small Non-Coding RNA (miR-21/124) Modulates Expression of Runt-Related Transcriptional Factor 2 and Osteopontin, Promoting Regeneration of Osteoporotic Bone in Bilateral Cranial Defects in a Senescence-Accelerated Mouse Model (SAM/P6). PART 2

“…1,2 The advancement in the field of osteoporosis treatment and prevention is undeniable, however, bone fracture regeneration in osteoporotic/geriatric patients is still problematic, hence requires novel therapeutic strategies. [3][4][5] At the molecular level, the disease is triggered by an imbalance between the activity of bone-forming and resorbing cells. 6,7 In bone formation, mesenchymal stromal stem cells (MSCs), which can differentiate into preosteoblast populations and play a fundamental role in initiating tissue regeneration, represent one of the most promising therapeutic targets.…”

“…Abbreviations: nHAp, nanohydroxyapatite; IOs, iron oxide nanoparticles; miR, microRNA; RT-qPCR, quantitative polymerase chain reaction followed by reverse transcription; XRPD, X-ray powder diffraction; MF, magnetic field; Runx-2, runt-related transcription factor 2; Coll-1, collagen type 1; OPG, osteoprotegerin; Bcl-2, B-cell lymphoma 2; BAX, Bcl-2 associated X protein; Sost, sclerostin; Dmp1, dentin matrix protein 1; TRAP, tartrate-resistant acid phosphatase; OPN, osteopontin; ALP, alkaline phosphatase; CAII, anhydrase II; Ctsk, cathepsin K; Gapdh, glyceraldehyde3-phosphate dehydrogenase; snU6, small nuclear; RNA OCN, osteonectin; ECM, extracellular matrix; DAPI, [4ʹ,6-diamidino-2-phenylindole]. International Journal of Nanomedicine 2021:16 https://doi.org/10.2147/IJN.S316240 DovePress 6053 Dovepress Marycz et al Powered by TCPDF (www.tcpdf.org) International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 44.224.250.200 on 08-Sep-2021 For personal use only.…”